University of California, San Diego Rady Children's Hospital
Welcome,         Profile    Billing    Logout  
 16 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Levy, Michael
PET-AON, NCT06453694: Efgartigimod for the Treatment of Acute Optic Neuritis

Not yet recruiting
2
20
US
Efgartigimod Alfa, Vyvgart Hytrulo, Placebo
Anastasia Vishnevetsky, MD, MPH, argenx
Optic Neuritis
12/26
07/27
SENS-NMO, NCT05974293: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Not yet recruiting
2
44
US
Nabiximols, Sativex, Placebo
Michael, Levy M.D.,Ph.D., Jazz Pharmaceuticals
NMO Spectrum Disorder, Spasticity, Muscle
04/26
09/26
NCT05549258 / 2021-003528-33: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Recruiting
2
15
Europe, Canada, US, RoW
Inebilizumab
Amgen, Horizon Therapeutics Ireland DAC
Neuromyelitis Optica Spectrum Disorder
04/27
04/27
Margol, Ashley
NCT03904862: Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Recruiting
1/2
66
US
CX 4945, Silmitasertib sodium
Pediatric Brain Tumor Consortium, Senhwa Biosciences, Inc., National Cancer Institute (NCI), St. Jude Children's Research Hospital, National Cancer Institute/NIH/DHHS (NCI)
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
12/29
02/30
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
PNOC017, NCT03749187: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting
1
78
US
PARP Inhibitor BGB-290, BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
University of California, San Francisco, BeiGene USA, Inc.
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
06/26
07/29
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
Yoon, Janet
AOST-2121, NCT04974008: Osteosarcoma Maintenance Therapy With OST31-164

Completed
2
39
US
OST31-164
George Clinical Pty Ltd
Bone Cancer
09/23
09/23
NCT05130255: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Recruiting
1
60
US
GD2-SADA:177Lu-DOTA Complex, two-step radioimmunotherapy
Y-mAbs Therapeutics
SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
03/27
04/27
Elster, Jennifer
SJATRT, NCT02114229: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Active, not recruiting
2
125
US
alisertib, methotrexate, MTX, cisplatin, Platinol-AQ, carboplatin, paraplatin, cyclophosphamide, cytoxan, etoposide, VP-16, Vepesid, Etoposide phosphate (Etopophos), topotecan, Hycamtin, vincristine, Oncovin, Surgical resection, surgical management, Radiation therapy, Craniospinal irradiation (CSI), Radiotherapy
St. Jude Children's Research Hospital, Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
09/25
09/27
PNOC029, NCT05465174: Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
56
US
Nivolumab, Opdivo, Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
PNOC017, NCT03749187: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting
1
78
US
PARP Inhibitor BGB-290, BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
University of California, San Francisco, BeiGene USA, Inc.
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
06/26
07/29
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
Elster, Janet
No trials found

Download Options